California-based Neurotrack develops clinically-validated cognitive assessment tools to detect cognitive impairment in patients. The tools test functions such as processing speed, recognition memory, associative learning, associative memory, inhibition, attention, and executive function. The tests, which use haptic and eye-tracking technology, can be used as early warning signs for detecting neurodegenerative diseases such as Alzheimer's and dementia in individuals. As of November 2022, the company has facilitated over 150,000 cognitive assessments through its platform and partners with both healthcare providers and health plans.
In November 2022, the company launched a three-minute digital assessment tool, which can screen patients for cognitive impairment during wellness consultations. Neurotrack also announced the formation of a new clinical advisory board to help refine the company’s offerings to better meet the needs of both patients and healthcare providers.
Key customers and partnerships
In March 2024, Neurotrack partnered with women's health clinic Midi Health to discern whether brain fog symptoms are related to menopause or early signs of dementia in women. Through the partnership, Midi Health patients gained access to a three-minute cognitive assessment by Neurotrack, called the Symbol Match test, that can be taken online on any device. Depending on test results, patients were either referred to other services for cognitive conditions or treated for brain fog by their clinician at Midi Health with adjustments in diet, lifestyle changes, or medication.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.